Stock Groups

U.S. FDA considering lowering recommended age for Pfizer/BioNTech COVID-19 boosters By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO : Nurses fill up syringes as patients receive coronavirus disease booster shots (COVID-19). This was done at a Pfizer BioNTech vaccine clinic in Southfield Michigan. It took place September 29th, 2021. REUTERS/Emily Elconin

NEW YORK, Reuters – The top U.S. Food and Drug Administration official stated on Friday that they are considering lowering recommendations for booster shots of Pfizer/BioNTech’s COVID-19 vaccine. This is based on Israeli data suggesting that vaccine effectiveness is declining.

Israeli scientists provided “data that appeared compelling in the 40 and above age range,” said Dr. Peter Marks (Director of FDA’s Enter for Biologics Evaluation and Research), speaking before the FDA’s Vaccines and Related Biological Products Advisory Committee.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]